Images
The newspaper “Expansión” highlights the round of funding valued at 1.5 M€ closed by the biotech Iproteos—co-founded by IRB Barcelona and the University of Barcelona—, based at the Barcelona Science Park.
The biotech will set aside this capital for the completion of the regulatory preclinical phase of a first-in-class drug for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS).
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
